Miragen Adds Myeloproliferative Disease Drug to Pipeline, Sees IND in 2012

The new program, which received orphan drug status earlier this year, grew out of an effort to track down microRNAs associated with heart attack, Miragen's CEO said this week.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.